Retinal Degeneration – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Retinal Degeneration – Drugs In Development, 2024 report and make more profitable business decisions.
Retinal degeneration refers to a group of diseases that cause progressive damage to the cells of the retina, the light-sensitive tissue at the back of the eye crucial for vision. These conditions lead to a gradual loss of vision, which can range from mild to severe and can eventually result in blindness. There are several types of retinal degenerative diseases, including:
Retinitis pigmentosa (RP): RP is a genetic disorder that affects the retina’s rod and cone cells, leading to a gradual loss of peripheral vision and difficulty seeing in low light. Over time, it can progress to tunnel vision or complete blindness.
Age-related macular degeneration (AMD): AMD primarily affects the macula, the central part of the retina responsible for detailed central vision. It is more common in older individuals and can lead to blurred or distorted central vision, making it difficult to read or recognize faces.
Stargardt disease: Stargardt disease is an inherited form of macular degeneration that usually manifests in childhood or adolescence. It causes progressive central vision loss due to the degeneration of the macula.
Choroideremia: Choroideremia is a rare genetic disorder affecting the retina’s photoreceptor cells, leading to progressive vision loss that typically begins in childhood and worsens over time.
Leber congenital amaurosis (LCA): LCA is a rare inherited disorder causing severe vision loss or blindness at birth or within the first few months of life. It affects the development of the retina and its ability to perceive light.
Symptoms of retinal degeneration can vary based on the specific condition and its stage, but they often include reduced night vision, difficulty seeing in low light, loss of peripheral or central vision, and, in some cases, changes in color perception.
The Retinal Degeneration drugs in development market research report provide comprehensive information on the therapeutics under development for Retinal Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinal Degeneration and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Retinal Degeneration | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 76 molecules, with 66 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Retinal Degeneration therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Retinal Degeneration pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Retinal Degeneration treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Abeona Therapeutics IncAbfero Pharmaceuticals Inc
AiVita Biomedical Inc
Alexandria University
Alia Therapeutics Srl
Apollo Therapeutics Ltd
Arctic Vision Shanghai Biotechnology Co Ltd
Argos Vision Inc
Army Medical University Hospital 1
Astellas Pharma Inc
Atsena Therapeutics Inc
Beacon Therapeutics Ltd
Beijing Chinagene Tech Co Ltd
Biovista Inc
CAMP Therapeutics Inc
Case Western Reserve University
Curative Biotechnology Inc
Daiichi Sankyo Co Ltd
Editas Medicine Inc
Evvia Therapeutics Inc
EyeCure Therapeutics Inc
Frontera Therapeutics Inc
Generation Bio Co
GenSight Biologics SA
Healx Ltd
Hopstem Biotechnology LLC
Hubble Therapeutics Inc
HuidaGene Therapeutics Co Ltd
Imbria Pharmaceuticals Inc
Innostellar Biotherapeutics Co Ltd
IVERIC bio Inc
Ixchel Pharma LLC
Life Biosciences Inc.
LuxFiat Therapeutics LLC
MeiraGTx Holdings Plc
Metro International Biotech LLC
Mitotech SA
Mogrify Ltd
Myto Therapeutics Inc
National Eye Institute
Neuroptika Inc
NutriForward LLC
Ocugen Inc
Odylia Therapeutics Inc
OkuloVision Inc
Opus Genetics Inc
Pharma Gateway AB
Polgenix Inc
ProQR Therapeutics NV
PYC Therapeutics Ltd
ReNeuron Group Plc
Shanghai Vitalgen BioPharma Co Ltd
Stealth BioTherapeutics Inc.
TeamedOn International Inc
Tel Aviv University
Unicocell Biomed Co Ltd
University of Florida
University of Miami Miller School of Medicine
Vall d’Hebron Institute of Research
Variant
VCCT Inc
Wuhan Neurophth Biological Technology Ltd
Zhongmou Therapeutics
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Retinal Degeneration reports